The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ESH 2017 | Combination therapies and improving overall survival in AML
This is an exciting time for acute myeloid leukemia (AML), with the introduction of numerous novel combination therapies and the overall survival of patients increasing. In this intriguing video, Mark Levis, MD, PhD, from The Johns Hopkins Hospital, Baltimore, MD, speaking from the International Conference on Acute Myeloid Leukemia 2017 in Estoril, Portugal by the European School of Hematology (ESH), discusses the most promising combination therapies and why he thinks that overall survival is increasing in AML.
